**GATA3 is downregulated in osteosarcoma and facilitates EMT as well as migration through regulation of slug**

Linjie Ma1
Wentao Xue1
Xianghai Ma2

1Department of Orthopedics, Yidu Central Hospital of Weifang City, Qingzhou 262500, People’s Republic of China; 2Department of Orthopedics, People’s Hospital of Juxian, Juxian, Shandong 276500, People’s Republic of China

**Background:** GATA3 functions as a tumor suppressor and has been observed in multiple types of cancer, but the effects and mechanisms of GATA3 in osteosarcoma (OS) are not yet known.

**Methods:** The GATA3 expression in OS cells and tissues were detected using quantitative reverse-transcription PCR and Western blotting assay. CCK-8 assay, colony formation assay, wound healing assay as well as transwell assay, were performed to determine the effects of GATA3 on cell proliferation, migration and invasion. ChIP and qChIP as well as luciferase assay were performed whether GATA3 transcriptionally regulated slug expression.

**Results:** GATA3 was downregulated in OS cells and tissues. The GATA3 expression was closely associated with tumor size as well as metastasis. GATA3 significantly suppressed OS cells proliferation, migration and invasion. EMT-associated transcript factor, slug, was transcriptionally inhibited by GATA3, thereby regulation of EMT in OS.

**Conclusion:** GATA3 serves as a tumor suppressor in OS and suppresses the progression and metastasis of OS through regulation of slug.

**Keywords:** GATA3, osteosarcoma, epithelial–mesenchymal transition, proliferation, migration

**Introduction**

Osteosarcoma (OS), a primary malignant bone cancer, occurs mainly in children and adolescents.1 The incidence of OS is approximately 30 new cases per million in the world annually.2,3 OS has a high propensity for lung metastases.4,5 Because of highly aggressive and rapid metastases, the patients with OS have a 3–5 year survival rate of 5%–20%.6 Therefore, it is necessary to further investigate the mechanisms underlying the occurrence, progression, invasion, and metastasis of OS.

GATA3, a transcript factor, belongs to the GATA family which comprises of six members that are expressed in a tissue-specific manner.8–13 Previous studies have revealed that GATA3 plays a key role in mammary epithelial cell differentiation as well as mammary gland homeostasis.8,9,14–16 Loss of GATA3 has been reported to promote breast cancer metastasis.17–22 However, the function of GATA3 in OS is not yet known.

Epithelial–mesenchymal transition (EMT) is a complex cellular process; the main characteristic of EMT is loss of cell polarity in epithelial cells as well as development of characteristics of interstitial cells, which promotes the migration and invasion ability of cancer cells. Multiple works have suggested that EMT is associated with OS metastasis.23–26
In the present study, we identified that GATA3 expression was downregulated in OS cell lines and tissues. GATA3 expression was remarkably associated with tumor size as well as metastasis and the prognosis of OS. Therefore, the effects and detailed molecular mechanism of GATA3 in OS progression were explored. The results indicated that ectopic expression of GATA3 was able to suppress cell proliferation, migration, and invasion in human OS cell lines. Moreover, GATA3 inhibited EMT in OS cell lines though regulation of slug expression. Therefore, it is proposed that GATA3 might as a tumor suppressor in OS development and as a potential therapeutic target.

**Materials and methods**

**Cell lines and culture**

The human OS cell lines, Saos2 and U2OS, and human fetal osteoblastic cell lines 1.19 (hFOB 1.19) and HEK-293T were purchased from American Type Culture Collection (Manassas, VA, USA). Saos2, U2OS, and HEK-293T cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco, Los Angeles, CA, USA) supplemented with 10% fetal bovine serum (FBS; HyClone, Logan, UT, USA) at 37°C in a humidified atmosphere with 5% CO₂. The hFOB 1.19 cells were cultured in DMEM/Ham’s F-12 (HyClone) supplemented with 10% FBS and geneticin (400 mg/mL) at 34°C with 5% CO₂.

**Tissue specimens**

OS tissues and adjacent normal tissues were obtained from patients who were diagnosed as having OS. All patients had not received any treatment of radiotherapy or chemotherapy before the surgical excision. These tissue samples were immediately frozen in liquid nitrogen before using. Our studies were approved by the institutional ethics committee of People’s Hospital of Juxian. Written informed consent was obtained from each patient.

**Transfections**

Briefly, U2OS and Saos2 cells were placed in six-well culture plates at a concentration of 2 × 10⁵ cells/well. Following 24 hours of culturing (70% confluence), cells were transfected with 2.5 µg vector or FLAG-GATA3 plasmid or 50 nM scramble siRNA or GATA3 siRNA using Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. After transfection for 48 hours, the transfection efficiency was determined by quantitative reverse-transcription PCR (qRT-PCR) and western blotting assay. The experiments were independently repeated three times.

**Western blotting analysis**

U2OS and Saos2 cells were transfected with FLAG-GATA3 plasmid or GATA3 siRNA for 48 hours. Subsequently, cells were collected and lysis by RIPA protein extraction reagent supplemented with a protease inhibitor cocktail (Roche, Pleasanton, CA, USA). The concentration of protein was quantified using the BCA Protein Quantification kit (Pierce, Waltham, MA, USA) according to the manufacturer’s instructions. A total of 40 µg protein was separated by 10% SDS-PAGE and transferred to nitrocellulose membranes (Sigma-Aldrich Co., St Louis, MO, USA). The membranes were blocked with 5% skim milk (OriGene Technologies, Inc., Beijing, People’s Republic of China) for 1 hour at room temperature. Subsequently, the membranes were incubated with antibodies, such as GATA3 (1:2,000, Abcam, Cambridge, UK), E-cadherin antibody (1:2,000, Abcam), N-cadherin antibody (1:2,000, Abcam), vimentin antibody (1:2,000, Abcam), slug (1:1,000, Abcam), snail (1:2,000, Abcam), twist1 (1:1,000, Abcam), and β-actin antibody (1:5,000, Abcam) overnight at 4°C. After washing with TBST buffer three times, the membranes were incubated with horseradish peroxidase-coupled (HRP) secondary antibody (1:5,000, Abcam) at room temperature for 1 hour. Finally, the blots were visualized using Western Lighting Chemiluminescence Reagent Plus (PerkinElmer, Inc., Waltham, MA, USA).

**qRT-PCR**

Total RNA was extracted from OS cells and tissues using TRIzol reagent (Invitrogen, Carlsbad, CA, USA; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer’s protocol. The RNA was reverse transcribed by using the High-Capacity RNA-to-cDNA™ kit (Thermo Fisher Scientific, Inc.). qPCR analysis was performed using SYBR-Green Mix (Roche Diagnostics). The primer sequences were as follows: GATA3 forward: 5′-GGTTCACAAATATTACAGACCC-3′, reverse: 5′-TTAAACAGAGCTGTCTTGGG-3′; E-cadherin forward: 5′-TACGCCTGGGACTCCACCTA-3′, reverse: 5′-CCAGAAACGGAGCCCTGAT-3′; N-cadherin, forward: 5′-CGAGGCGGCTGCTGCCAC-3′, reverse: 5′-CGCTGCTCTCCGCTCCCCGC-3′; vimentin forward: 5′-TACAGGAAAGCTGAAAGG-3′, reverse: 5′-ACCAGAGGGAGTGAATCCAG-3′; GAPDH forward:
5'-CGGAGTCAACGGATTTGGTG-3', reverse, 5'-AGCCCTTCTCCATGGTGAGAC-3'. The ther-
mocycling conditions were as follows: 95°C for 5 minutes
and 30 seconds, and 40 cycles (15 seconds at 95°C, 1 minute
at 60°C). Relative mRNA expression was calculated using
2-ΔΔCq method.\(^7\)

**Colony forming assay**

After transfection for 48 hours, approximately 5×10\(^4\) U2OS or
Saos2 cells were placed in six-well plates and incubated with
serum-free DMEM medium for 14 days, then the colonies
were stained with 0.1% crystal violet at room temperature
for 15 minutes. The numbers of colonies (cells >50) were
counted in six randomly selected microscopic fields. The experiments
were independently repeated three times.

**Cell viability assay**

CCK8 assay was performed to evaluate cell viability. Transfected U2OS and Saos2 cells were placed in a 96-well plate with 200 µL DMEM medium at a concentration of 3×10\(^4\) cells/well. Twenty microliter CCK8 solution (Beyo-
time, Jiangsu, People’s Republic of China) was added to
each well at 0, 24, 48, and 72 hours. After incubating for
30 minutes, the absorbance 450 nm was measured on a
microplate reader. The experiments were independently
repeated three times.

**Transwell invasion assay**

Transwell invasion assay was performed to determine the
effect of GATA3 on cell invasion ability. Briefly, 3×10\(^5\) transfection U2OS or
Saos2 cells in 400 µL serum-free DMEM medium were placed into the upper chamber coated
with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA). The lower chamber contained 500 µL DMEM media con-
taining 10% FBS. After incubation at 37°C for 18 hours, the cells remaining on the upper membrane were removed
with a cotton swab, and the cells that had invaded through
the membrane were stained with 0.1% crystal violet at room temperature for 10 minutes. The number of invad cells
was counted using a light microscope. The experiments were
independently repeated three times.

**Wound healing assay**

Wound healing assay was performed to determine the effect
of GATA3 on cell migration ability. In brief, transfected
U2OS and Saos2 cells were placed into each well of 12-well
plates, and then, a straight-line wound was created using a
pipette tip when cell layers reached confluence. Then, cells
were washed with cold-PBS three times and cultured in
serum-free DMEM medium for 48 hours. The closure of the
wounds was evaluated by light microscopy. The experiments
were independently repeated three times.

**Luciferase reporter assays**

The pGL3-basic vector was purchased from Promega
(Madison, WI, USA) and used for luciferase reporter assay. The
promoter region target of slug was cloned into the
pGL3-basic (pGL3-slug). HEK-293T cells were placed in a
24-well plate at a concentration of 1×10\(^5\) cells/well and were
cotransfected with pGL3-slugand vector or FLAG-GATA3
plasmid using Lipofectamine 2000 (Invitrogen). After trans-
fection for 24 hours, the luciferase activities were determined
using Dual Luciferase Reporter Assay System (Promega)
according to manufacturer’s protocol. The experiments were
independently repeated three times.

**Statistical analyses**

Statistical analyses were performed using SPSS software.
One-way analysis of variance was used in multiple group
analysis, and paired \(t\)-test was adopted to assess data
between two experimental groups. Overall survival curves
were estimated by the Kaplan–Meier method and compared
by the log-rank test. Data are expressed as the mean ± SD.
*\(p<0.05\) was considered to indicate a statistically significant
difference.

**Result**

**GATA3 downregulates in OS tissues and cells; OS patients with high level of GATA3 had better prognosis**

To determine the function of GATA3 in OS, we first detected
the expression of GATA3 in OS cells and OS tissues using
qRT-PCR and Western blotting assay and compared these
with those levels in hFOB 1.19 cells and normal tissues. The
results of qRT-PCR and Western blotting suggested that the
expression of GATA3 in OS cells and OS tissues was obvious-
ly lower than that in hFOB 1.19 cells and normal tissues, respectively (Figure 1A and B). Subsequently, we divided
patients with OS into two groups, low expression of GATA3
group and high expression of GATA3 group, to analyze
the relationship between GATA3 expression and overall
survival of patients with OS using Kaplan–Meier survival
assay. The results showed that high expression of GATA3
was correlated with high overall survival rate for patients
GATA3 inhibits proliferation of OS cells in vitro

To further decipher the function of GATA3 on cell proliferation, we first overexpressed or knocked down GATA3 in U2OS and Saos2 cells using FLAG-GATA3 plasmid or GATA3 siRNA, respectively. The expression of GATA3 with OS (Figure 1C, *P* = 0.039). Meanwhile, the expression of GATA3 was associated with tumor size and tumor stage as well as metastasis stage (Table 1). Our findings suggest that GATA3 is downregulated in OS cells and tissues, and the expression of GATA3 is associated with the prognosis of OS patients.
was determined by qRT-PCR and western blotting assay (Figure 2A and B). The functions of GATA3 in OS cells were evaluated using the CCK-8 proliferation assay and colony formation assay. The proliferative capability of OS cells was detected at 0, 24, 48, and 72 hours. The results indicated that ectopic expression of GATA3 inhibited the proliferative capability of OS cells compared with control group; however, inhibition of GATA3 promoted the proliferative capability of OS cells compared with control group, and the difference was more apparent at 72 hours (Figure 2C).

Similar results were observed in colony formation assay; the number of colonies were decreased when cells were transfected with FLAG-GATA3 plasmid, compared with control group; however, inhibition of GATA3 increased the number of colonies, compared with control group (Figure 2D). These results suggest that overexpression of GATA3 inhibits proliferation of OS cells.

**GATA3 inhibits migration and invasion of OS cells in vitro**

Subsequently, we determined whether GATA3 regulated the migration and invasion of OS cells using wound healing assay and transwell invasion assay. The results of wound healing assay suggested that overexpression of GATA3 significantly decreased the relative distance of cell migration; however, inhibition of GATA3 obviously increased the relative distance of cell migration (Figure 3A). The results of transwell invasion assay were also consistent with wound healing assay, indicating that ectopic expression of GATA3 suppressed the invasion capability of U2OS and Saos2 cells compared with control group; however, inhibition of GATA3 promoted the invasion capability of OS cells compared with control group (Figure 3B). Taken together, our findings show that overexpression of GATA3 inhibits migration and invasion of OS cells in vitro.

**Overexpression of GATA3 upregulates E-cadherin and downregulates the expression of N-cadherin and vimentin in OS cells**

EMT is a complex progress which is associated with cancer metastasis. To evaluate the effect of GATA3 on EMT, proteins related to EMT, including E-cadherin, N-cadherin, and vimentin, were detected using qRT-PCR and western blotting assay. The mRNA and protein levels of E-cadherin were obviously reduced, whereas mRNA and protein levels of N-cadherin and vimentin were all dramatically raised when cells were transfected with FLAG-GATA3 plasmid (Figure 4A and B) in U2OS and Saos2. Moreover, immunofluorescence assay also confirmed that ectopic expression of GATA3 increased the expression of E-cadherin and decreased the expression of vimentin (Figure 4C). However, the mRNA and protein levels of E-cadherin were obviously increased, whereas the mRNA and protein levels of N-cadherin and vimentin were all dramatically decreased when cells were transfected with GATA3 shRNA to stably knock down GATA3 (Figure 4D and E), suggesting that overexpression of GATA3 may suppress EMT of OS cells.

**GATA3 is a direct transcriptional repressor of slug in OS tissues**

EMT-associated transcription factors, such as slug, snail, and twist1, have been reported to play key roles in EMT. So, we next detected whether GATA3 regulated those transcription factors. As shown in Figure 5A and B, we found that both mRNA and protein levels of slug were decreased when U2OS and Saos2 cells transfected with FLAG-GATA3 plasmid; however, overexpression of GATA3 had no effect on the expression of snail and twist1 (Figure 5A and B). GATA3, as a transcription factor, we assumed might transcriptionally regulate slug. Subsequently, we performed ChiP and qChiP assay to determine whether GATA3 bound the promoter region of slug. The results demonstrated that GATA3 could bind the promoter region of slug (Figure 5C). Subsequently, we cloned the promoter region of slug into pGL3-basic plasmid (pGL3-slug). HEK 293 T cells were

<table>
<thead>
<tr>
<th>Variables</th>
<th>n=65</th>
<th>GATA3 expression</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Low (n=41)</td>
<td>High (n=24)</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>38</td>
<td>24</td>
<td>14</td>
</tr>
<tr>
<td>Female</td>
<td>27</td>
<td>17</td>
<td>10</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;20</td>
<td>29</td>
<td>20</td>
<td>9</td>
</tr>
<tr>
<td>≥20</td>
<td>36</td>
<td>21</td>
<td>15</td>
</tr>
<tr>
<td>Tumor size</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥5 cm</td>
<td>40</td>
<td>30</td>
<td>10</td>
</tr>
<tr>
<td>&lt;5 cm</td>
<td>25</td>
<td>11</td>
<td>14</td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I–II</td>
<td>32</td>
<td>16</td>
<td>16</td>
</tr>
<tr>
<td>III–IV</td>
<td>33</td>
<td>25</td>
<td>8</td>
</tr>
<tr>
<td>Metastasis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>36</td>
<td>28</td>
<td>8</td>
</tr>
<tr>
<td>No</td>
<td>29</td>
<td>13</td>
<td>16</td>
</tr>
<tr>
<td>Slug expression</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High</td>
<td>40</td>
<td>30</td>
<td>10</td>
</tr>
<tr>
<td>Low</td>
<td>25</td>
<td>11</td>
<td>14</td>
</tr>
</tbody>
</table>

Abbreviation: OS, osteosarcoma.
Figure 2 Overexpression of GATA3 inhibits proliferation of OS cells in vitro.

Notes: (A, B) GATA3 was overexpressed or knocked down in U2OS and Saos2 cells, respectively. After transfection for 48 hours, the expression of GATA3 was determined using qRT-PCR and western blotting assay. *<0.05, vs vector or scramble siRNA. (C) The effect of GATA3 on OS cell proliferation was evaluated within 72 hours using CCK-8 assay. *<0.05, vs vector or scramble siRNA. (D) The effect of GATA3 on OS cell proliferation was evaluated using colony formation assay. *<0.05, vs vector or scramble siRNA.

Abbreviations: qRT-PCR, quantitative reverse-transcription PCR; OS, osteosarcoma.
GATA3 facilitates EMT and migration in osteosarcoma

**Figure 3** GATA3 inhibits migration and invasion of OS cells in vitro.

Notes: (A) GATA3 was overexpressed or knocked down in U2OS and Saos2 cells, respectively. After transfection for 48 hours, the effect of GATA3 on OS cell migration was assessed using wound healing assay. *P<0.05, vs vector or scramble siRNA. (B) GATA3 was overexpressed or knocked down in U2OS and Saos2 cells, respectively. After transfection for 48 hours, the effect of GATA3 on OS cell migration was assessed using Transwell invasion assay. *P<0.05, vs vector or scramble siRNA.

Abbreviation: OS, osteosarcoma.

cultured and cotransfected with pGL3-slug and vector or GATA3 plasmid. The relative luciferase activity was obviously decreased in cells with FLAG-GATA3 plasmid, compared with cells treated with vector (Figure 5D). We also determined the expression of slug in U2OS, Saos2, and hFOB 1.19 cells and found slug expression was the opposite of that of GATA3 (Figure 5E); moreover, we found the slug expression was negatively correlated with GATA3 expression in OS tissues (Table 1). Taken together, our work indicate that slug is a direct target of GATA3 and GATA3 can downregulate the expression of slug in OS.

**Discussion**

Accumulating evidence has shown that GATA3 play key roles in cancer development. Here, we first revealed that GATA3 was downregulated in OS. CCK-8 assay and colony formation assay demonstrated that GATA3 inhibited OS cells proliferation.
Figure 4 GATA3 upregulates E-cadherin and downregulates the expression of N-cadherin and vimentin in OS cells.

Notes: (A, B) GATA3 was overexpressed in U2OS and Saos2 cells. The expression of EMT markers, such as epithelial marker (E-cadherin) and mesenchymal markers (N-cadherin and vimentin), were detected by qRT-PCR and western blotting assay. *<0.05, vs vector. (C) GATA3 was overexpressed in U2OS and Saos2 cells. The expression of E-cadherin and vimentin were detected by immunofluorescence assay using anti-E-cadherin and anti-vimentin antibodies. (D, E) GATA3 was stable knocked down in U2OS and Saos2 cells using two GATA3 shRNA. The expression of GATA3 and EMT markers were detected by qRT-PCR and western blotting assay. *<0.05, vs shControl.

Abbreviations: EMT, epithelial–mesenchymal transition; qRT-PCR, quantitative reverse-transcription PCR; OS, osteosarcoma.
GATA3 facilitates EMT and migration in osteosarcoma

Figure 5 GATA3 is a direct transcriptional repressor of slug in OS tissues.

Notes: (A, B) GATA3 was overexpressed in U2OS and Saos2 cells. The expression of EMT-associated transcription factors, including slug, snail, and twist1, were detected using qRT-PCR and western blotting assay. *<0.05, vs vector. (C) ChIP and qChIP assay was performed to determine whether GATA3 could bind the promoter region of slug. *<0.05, vs IgG. (D) Luciferase reporter assay was performed to determine whether GATA3 transcriptionally regulated slug. *<0.05, vs vector. (E) The expression of slug in OS cell lines using qRT-PCR, *P<0.05, vs hFOB 1.19 cells.

Abbreviations: EMT, epithelial–mesenchymal transition; qRT-PCR, quantitative reverse-transcription PCR; OS, osteosarcoma.

Then analyses of OS cells migration and invasion reveal that overexpression of GATA3 can effectively suppress the migration and invasion abilities of OS cells. In addition, ectopic expression of GATA3 promoted E-cadherin expression but decreased the expression of N-cadherin and vimentin in OS cells in vitro. E-cadherin is an epithelial marker, and downregulation of E-cadherin will increase the cellular motility, leading cancer cells to enter into mesenchymal
state as well as metastasize.\textsuperscript{31} N-cadherin and vimentin are markers of cancer cells undergoing an EMT and play a role in migration.\textsuperscript{32,33} Thus, GATA3 acts as a tumor suppressor in OS and inhibits migration and invasion through suppressing EMT. At last, ChIP and qChIP assays as well as dual luciferase assay revealed that slug was a downstream target of GATA3 and that GATA3 could downregulate the slug expression in OS cells. Slug is a transcription factor which promotes EMT in multiple cancers.\textsuperscript{34} Therefore, GATA3 suppressed EMT through regulation of slug in OS.

However, there are still some limitations in our work. First, immunohistochemistry of GATA3 in the normal and OS samples need to be further investigated, as this is a better way to illustrate the expression of GATA3 in OS. Second, although our findings suggested that GATA3 could suppress cell proliferation, migration, and invasion in OS cells in vitro, whether GATA3 plays the same roles in vivo is not yet known. So, it is necessary to perform in vivo experiments to further explore the functions of GATA3. Additionally, the other upstream molecules of GATA3 and other downstream targets of GATA3 should be investigated.

In summary, GATA3 serves as a tumor suppressor in OS. GATA3 is downregulated in OS and the expression of GATA3 is associated with tumor size and metastasis. Overexpression of GATA3 not only inhibits the proliferation of OS cells but also suppresses OS cells migration and invasion. Furthermore, GATA3 can directly downregulate the EMT-related transcription factor, slug, expression. We thus present GATA3 as a potential therapeutic target.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


